You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Neglected diseases, such as African Sleeping Sickness, have a big impact on human health and cause a major economic burden on developing countries. The parasites that cause sleeping sickness depend on enzymes called 'phosphodiesterases'. Distortion of the function of these enzymes is lethal for the parasites, which makes the enzyme a potential drug target.
Developing drugs for these diseases is commercially not feasible for a single company but the social need is very high. With support and advocacy of TI Pharma, an international partnership was started that brings together all relevant expertise to develop a possible treatment.
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board